Nautilus Biotechnology Inc. has launched an Early Access Program for its novel single-molecule proteomics platform, marking a significant step toward commercialization. The program debuts with a tau proteoforms assay aimed at advancing Alzheimer’s and neurodegenerative disease research. Participants will receive support from Nautilus in data interpretation and analysis, and the company is also offering exclusive development partnerships for custom assay creation. This expansion demonstrates Nautilus’ readiness to provide its high-resolution proteomics technology to external researchers and supports further growth in targeted and broadscale proteomic analyses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622033) on January 08, 2026, and is solely responsible for the information contained therein.